These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 39188060

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway.
    Zhang X, He Y, Jiang Y, Bao Y, Chen Q, Xie D, Yu H, Wang X.
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184076
    [Abstract] [Full Text] [Related]

  • 3. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y, Zhang L, Guo L, Wu C, Zhou J, Zhou Y, Ma J, Li X, Ji P, Wang M, Zhu W, Shi C, Li S, Wu W, Zhu W, Xiao D, Fu C, He Q, Sun R, Mao X, Lizaso A, Li B, Han-Zhang H, Zhang Z.
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS, Chung JH.
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C, Dong X, Lu H, Tong F, Chen L, Zhang R, Dong J, Hu Y, Wu G, Dong X.
    J Exp Clin Cancer Res; 2019 Feb 21; 38(1):95. PubMed ID: 30791942
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
    Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G.
    Lung Cancer; 2024 Feb 21; 188():107453. PubMed ID: 38160515
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL, Jia RN, Han K, Zhang YX.
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun 08; 53(6):578-584. PubMed ID: 38825903
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
    Zhang H, Sun FH, Chen ZC, Wang Q.
    Zhonghua Wai Ke Za Zhi; 2022 Jun 01; 60(6):580-586. PubMed ID: 35658346
    [Abstract] [Full Text] [Related]

  • 18. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    Caso R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, Zhou J, Jones GD, Nguyen B, Schultz N, Connolly JG, Brandt WS, Bott MJ, Rocco G, Molena D, Isbell JM, Liu Y, Mayo MW, Adusumilli PS, Travis WD, Jones DR.
    J Thorac Oncol; 2020 Dec 01; 15(12):1844-1856. PubMed ID: 32791233
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.